Overview

This trial is active, not recruiting.

Condition stroke
Treatment far infrared radiation
Phase phase 1
Sponsor GAAD Medical Research Institute Inc.
Start date May 2008
End date May 2010
Trial size 10 participants
Trial identifier NCT00675155, GAAD-SR-CTP1

Summary

A stroke is a sudden loss of brain function. It is caused by the interruption of flow of blood to the brain (ischemic stroke) or the rupture of blood vessels in the brain (hemorrhagic stroke). This study will investigate the use of far infrared radiation for stroke rehabilitation.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
far infrared radiation Far Infrared Radiation
Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.

Primary Outcomes

Measure
Management and Cure of Stroke
time frame: 2 Years

Secondary Outcomes

Measure
Rehabilitation of the following: ability to move, see, remember, speak, reason and read and write.
time frame: 2 Years

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - People with Stroke Exclusion Criteria: - None

Additional Information

Official title Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Stroke Rehabilitation
Principal investigator Ken Nedd, M.D.
Description A stroke is a sudden loss of brain function. The interruption of blood flow or the rupture of blood vessels causes brain cells (neurons) in the affected area to die. The effects of a stroke depend on where the brain was injured, as well as how much damage occurred. A stroke can impact any number of areas including your ability to move, see, remember, speak, reason and read and write. It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people with stroke.
Trial information was received from ClinicalTrials.gov and was last updated in January 2009.
Information provided to ClinicalTrials.gov by GAAD Medical Research Institute Inc..